IP Verse

Novel Pharmaceutical Composition - EP3090730B9

PatentPatent Analysis

EP3090730

NOVARTIS
Application Number
EP15199469A
Filing Date
Aug 1, 2007
Status
Granted And Under Opposition
Mar 8, 2024
Grant Date
Jul 3, 2024
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3143995B2
EP4321157B1
EP3487881B1

Bibliography

The patent EP3090730B9 was granted to Novartis on Jul 3, 2024 following the initial filing on Aug 1, 2007 under the application number EP15199469A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEJan 10, 2025ADMISSIBLE
HAMM & WITTKOPPJan 10, 2025ADMISSIBLE
KILBURN & STRODEJan 10, 2025ADMISSIBLE
MAIWALDJan 10, 2025ADMISSIBLE
ZENTIVA KSJan 10, 2025ADMISSIBLE
GALENICUM HEALTH SLUJan 9, 2025ADMISSIBLE
SCORPIOJan 9, 2025ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents